#daurismo

FDA approves new treatment for patients with acute myeloid leukemia

FDA approves new treatment Daurismo (glasdegib) for patients with acute myeloid leukemia The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic…